Identification of Hirsutine as an anti-metastatic phytochemical by targeting NF-κB activation

被引:38
作者
Lou, Chenghua [1 ]
Takahashi, Kei [2 ]
Irimura, Tatsuro [2 ,3 ]
Saiki, Ikuo [1 ]
Hayakawa, Yoshihiro [1 ,2 ]
机构
[1] Toyama Univ, Inst Nat Med, Dept Biosci, Div Pathogen Biochem, Toyama 9300194, Japan
[2] Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Canc Biol & Mol Immunol, Tokyo 1130033, Japan
[3] St Lukes Int Univ, Inst Med Innovat, Tokyo 1040044, Japan
关键词
metastasis; NF-kappa B; migration; invasion; matrix metalloproteinase; CELL-CYCLE ARREST; NATURAL-PRODUCTS; IKK-ALPHA; CANCER; MAGNOLOL; APOPTOSIS; INHIBITION; EXPRESSION; PATHWAY; RESVERATROL;
D O I
10.3892/ijo.2014.2624
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Nuclear factor-kappa B (NF-kappa B) activation has been implicated not only in carcinogenesis but also in cancer cell invasion and metastatic process; therefore, targeting the NF-kappa B pathway is an attractive strategy for controlling metastasis. Amongst 56 chemically defined compounds derived from natural products, we have identified a new phytochemical compound Hirsutine, which strongly suppresses NF-kappa B activity in murine 4T1 breast cancer cells. In accordance with the NF-kappa B inhibition, Hirsutine reduced the metastatic potential of 4T1 cells, as seen in the inhibition of the migration and invasion capacity of 4T1 cells. Hirsutine further inhibited the constitutive expression of MMP-2 and MMP-9 in 4T1 cells, and reduced the in vivo lung metastatic potential of 4T1 cells in the experimental model. Given that the migration of human breast cancer cells was also inhibited, our present study implies that Hirsutine is an attractive phytochemical compound for reducing metastasis potential of cancer cells by regulating tumor-promoting NF-kappa B activity.
引用
收藏
页码:2085 / 2091
页数:7
相关论文
共 50 条
  • [31] A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo
    Trebing, Johannes
    Lang, Isabell
    Chopra, Martin
    Salzmann, Steffen
    Moshir, Mahan
    Silence, Karen
    Riedel, Simone S.
    Siegmund, Daniela
    Beilhack, Andreas
    Otto, Christoph
    Wajant, Harald
    MABS, 2014, 6 (01) : 297 - 308
  • [32] Relevance of new drug discovery to reduce NF-κB activation in cardiovascular disease
    Madonna, Rosalinda
    De Caterina, Raffaele
    VASCULAR PHARMACOLOGY, 2012, 57 (01) : 41 - 47
  • [33] The NF-κB activation pathways, emerging molecular targets for cancer prevention and therapy
    Lin, Yong
    Bai, Lang
    Chen, Wenjie
    Xu, Shanling
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2010, 14 (01) : 45 - 55
  • [34] NF-κB-Activated miR-574 Promotes Multiple Malignant and Metastatic Phenotypes by Targeting BNIP3 in Thyroid Carcinoma
    Zhang, Zhe-Jia
    Xiao, Qian
    Li, Xin-Ying
    MOLECULAR CANCER RESEARCH, 2020, 18 (07) : 955 - 967
  • [35] Beyond NF-κB activation: nuclear functions of IκB kinase α
    Huang, Wei-Chien
    Hung, Mien-Chie
    JOURNAL OF BIOMEDICAL SCIENCE, 2013, 20 : 3
  • [36] Identification of anti-metastatic drug and natural compound targets in isogenic colorectal cancer cells
    Lee, Jin-Gyun
    McKinney, Kimberly Q.
    Pavlopoulos, Antonis J.
    Park, Jeong-Hill
    Hwang, Sunil
    JOURNAL OF PROTEOMICS, 2015, 113 : 326 - 336
  • [37] Combination Chemotherapy of Nafamostat Mesilate with Gemcitabine for Pancreatic Cancer Targeting NF-κB Activation
    Uwagawa, Tadashi
    Chiao, Paul J.
    Gocho, Takeshi
    Hirohara, Shouichi
    Misawa, Takeyuki
    Yanaga, Katsuhiko
    ANTICANCER RESEARCH, 2009, 29 (08) : 3173 - 3178
  • [38] Targeting NF-κB Signaling for Multiple Myeloma
    Wong, Ada Hang-Heng
    Shin, Eun Myoung
    Tergaonkar, Vinay
    Chng, Wee-Joo
    CANCERS, 2020, 12 (08) : 1 - 20
  • [39] Flavokawain B inhibits NF-κB inflammatory signaling pathway activation in inflammatory bowel disease by targeting TLR2
    Chen, Yi
    Jin, Tianyang
    Zhang, Mengpei
    Hong, Bo
    Jin, Bo
    Hu, Chenghong
    Wang, Jiong
    Chen, Yue
    Zhang, Lingxi
    Wang, Yi
    Huang, Lijiang
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2024, 486
  • [40] MiR-520b inhibits endothelial activation by targeting NF-κB p65-VCAM1 axis
    Yang, Bin
    Yang, Huijun
    Lu, Xiaomei
    Wang, Laiyuan
    Li, Hongfan
    Chen, Shufeng
    Wang, Xianqiang
    Shen, Chenyang
    Huang, Jianfeng
    Lu, Xiangfeng
    Gu, Dongfeng
    BIOCHEMICAL PHARMACOLOGY, 2021, 188